KR101100826B1 - 대사성 질병 치료용 글루코코티코이드 수용체 리간드 - Google Patents

대사성 질병 치료용 글루코코티코이드 수용체 리간드 Download PDF

Info

Publication number
KR101100826B1
KR101100826B1 KR1020047020680A KR20047020680A KR101100826B1 KR 101100826 B1 KR101100826 B1 KR 101100826B1 KR 1020047020680 A KR1020047020680 A KR 1020047020680A KR 20047020680 A KR20047020680 A KR 20047020680A KR 101100826 B1 KR101100826 B1 KR 101100826B1
Authority
KR
South Korea
Prior art keywords
hydroxy
compound
hydrogen
methyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020047020680A
Other languages
English (en)
Korean (ko)
Other versions
KR20050016588A (ko
Inventor
토마스 더블유. 본겔던
제임스 티. 링크
노아 투
필립 알. 킴
춘키우 라이
스티븐 티. 리차드스
피어 비. 제이콥슨
리차드 디. 비숍
브래들리 디. 게이츠
Original Assignee
카로 바이오 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/460,491 external-priority patent/US7141559B2/en
Application filed by 카로 바이오 아베 filed Critical 카로 바이오 아베
Publication of KR20050016588A publication Critical patent/KR20050016588A/ko
Application granted granted Critical
Publication of KR101100826B1 publication Critical patent/KR101100826B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020047020680A 2002-06-19 2003-06-17 대사성 질병 치료용 글루코코티코이드 수용체 리간드 Expired - Fee Related KR101100826B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17475002A 2002-06-19 2002-06-19
US10/174,750 2002-06-19
US10/460,491 2003-06-12
US10/460,491 US7141559B2 (en) 2002-06-19 2003-06-12 Glucocorticoid receptor ligands for the treatment of metabolic disorders
PCT/US2003/019157 WO2004000869A1 (en) 2002-06-19 2003-06-17 Glucocorticoid receptor ligands for the treatment of metabolic disorders

Publications (2)

Publication Number Publication Date
KR20050016588A KR20050016588A (ko) 2005-02-21
KR101100826B1 true KR101100826B1 (ko) 2012-01-02

Family

ID=30002639

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020047020680A Expired - Fee Related KR101100826B1 (ko) 2002-06-19 2003-06-17 대사성 질병 치료용 글루코코티코이드 수용체 리간드

Country Status (16)

Country Link
EP (1) EP1551860B1 (enExample)
JP (1) JP4611019B2 (enExample)
KR (1) KR101100826B1 (enExample)
CN (1) CN100348609C (enExample)
AR (1) AR040278A1 (enExample)
AT (1) ATE346082T1 (enExample)
AU (1) AU2003243622B9 (enExample)
CA (1) CA2488535C (enExample)
CY (1) CY1105982T1 (enExample)
DE (1) DE60309909T2 (enExample)
DK (1) DK1551860T3 (enExample)
ES (1) ES2278195T3 (enExample)
PT (1) PT1551860E (enExample)
TW (1) TWI285646B (enExample)
UY (1) UY27862A1 (enExample)
WO (1) WO2004000869A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7253283B2 (en) 2004-01-16 2007-08-07 Bristol-Myers Squibb Company Tricyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7605264B2 (en) 2004-01-16 2009-10-20 Bristol-Myers Squibb Company Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7569689B2 (en) 2004-01-16 2009-08-04 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7326728B2 (en) 2004-01-16 2008-02-05 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κβ activity and use thereof
US7273881B2 (en) 2004-01-16 2007-09-25 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7625921B2 (en) 2004-01-16 2009-12-01 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7317024B2 (en) 2005-01-13 2008-01-08 Bristol-Myers Squibb Co. Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7642273B2 (en) 2005-01-13 2010-01-05 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7361654B2 (en) 2005-01-13 2008-04-22 Bristol-Myers Squibb Co. Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7411071B2 (en) 2005-01-13 2008-08-12 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
GB0514302D0 (en) * 2005-07-12 2005-08-17 Karobio Ab Improved crystalline material
EP2348857B1 (en) 2008-10-22 2016-02-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
AU2009309037A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CN102812011A (zh) 2009-11-16 2012-12-05 梅利科技公司 [1,5]-二氮杂环辛间四烯衍生物
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
MY159058A (en) 2011-02-25 2016-12-15 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agent
CN103957919B (zh) * 2011-09-19 2018-10-16 瑞士苏黎世联邦理工学院 RORγ调节剂
EP2880028B1 (en) 2012-08-02 2020-09-30 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
JP2016516004A (ja) 2013-02-22 2016-06-02 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗糖尿病二環式化合物
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
EP2781217A1 (en) * 2013-03-18 2014-09-24 ETH Zurich ROR gamma modulators
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CN105693808B (zh) * 2015-11-05 2018-03-16 华润紫竹药业有限公司 一种醋酸乌立妥原料药杂质及其制备方法和作为标准品的用途
FR3055627A1 (fr) * 2016-09-08 2018-03-09 Laboratoire Hra-Pharma Methode de preparation du compose cdb-3877
FR3055626B1 (fr) * 2016-09-08 2018-10-12 Hra Pharma Lab Procede de synthese d'un compose steroide comprenant un substituant n-methylaniline en position 11
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
US10968232B2 (en) 2016-12-20 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
CN114230627B (zh) * 2021-12-31 2023-09-15 湖南新合新生物医药有限公司 一种倍他米松环氧水解物中间体的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0489423A1 (de) * 1990-12-06 1992-06-10 Hoechst Aktiengesellschaft Gallensäurederivate, Verfahren zu ihrer Herstellung und Verwendung dieser Verbindung als Arzneimittel
US5462933A (en) 1989-09-14 1995-10-31 Hoechst Aktiengesellschaft Modified bile acid conjugates, and their use as pharmaceuticals
WO2000058337A1 (en) * 1999-03-27 2000-10-05 Karo Bio Ab Liver specific bile acid derivatives of the glucocorticoid antagonist ru486

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4000397A1 (de) * 1990-01-09 1991-07-11 Hoechst Ag Lipidselektive antioxidantien sowie deren herstellung und verwendung

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462933A (en) 1989-09-14 1995-10-31 Hoechst Aktiengesellschaft Modified bile acid conjugates, and their use as pharmaceuticals
EP0489423A1 (de) * 1990-12-06 1992-06-10 Hoechst Aktiengesellschaft Gallensäurederivate, Verfahren zu ihrer Herstellung und Verwendung dieser Verbindung als Arzneimittel
WO2000058337A1 (en) * 1999-03-27 2000-10-05 Karo Bio Ab Liver specific bile acid derivatives of the glucocorticoid antagonist ru486

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of Biological Chemistry (1992) Vol.267, pp.18598-18604

Also Published As

Publication number Publication date
WO2004000869A1 (en) 2003-12-31
CN1662549A (zh) 2005-08-31
AU2003243622A2 (en) 2004-01-06
EP1551860A1 (en) 2005-07-13
UY27862A1 (es) 2004-04-30
AU2003243622B9 (en) 2009-07-16
EP1551860B1 (en) 2006-11-22
CA2488535C (en) 2012-02-07
ATE346082T1 (de) 2006-12-15
AU2003243622A1 (en) 2004-01-06
DK1551860T3 (da) 2007-04-02
DE60309909D1 (de) 2007-01-04
AU2003243622B2 (en) 2009-05-28
TW200410983A (en) 2004-07-01
JP4611019B2 (ja) 2011-01-12
JP2005533807A (ja) 2005-11-10
TWI285646B (en) 2007-08-21
AR040278A1 (es) 2005-03-23
ES2278195T3 (es) 2007-08-01
CN100348609C (zh) 2007-11-14
CA2488535A1 (en) 2003-12-31
DE60309909T2 (de) 2007-06-21
PT1551860E (pt) 2007-02-28
CY1105982T1 (el) 2011-04-06
KR20050016588A (ko) 2005-02-21

Similar Documents

Publication Publication Date Title
KR101100826B1 (ko) 대사성 질병 치료용 글루코코티코이드 수용체 리간드
US5693769A (en) Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
FI66010C (fi) Foerfarande foer framstaellning av nya vid avbrytande av havandeskap anvaendbara 4- och/eller 6-alkylerade 4alfa 5alfa-epoxi-2alfa-cyan-3-oxosteroid-derivat
EP1989218B1 (en) 17-phosphorous steroid derivatives useful as progesterone receptor modulators
EP1989217B1 (en) 11-phosphorous steroid derivatives useful as progesterone receptor modulators
PL179460B1 (pl) sposób ich wytwarzania oraz srodki lecznicze zawierajace te zwiazki PL PL PL PL PL PL PL PL
FI89055C (fi) Foerfarande foer framstaellning av nya androstan-17-karboxylsyraestrar
CN1131238C (zh) 3－取代－d－高－1,3,5(10)－雌三烯衍生物
RU2234512C2 (ru) Соединенные с желчными кислотами производные пропаноламина, лекарственное средство
CA2171740C (en) 0rally active derivatives of 1,3,5(10)-estratriene
JPH03170497A (ja) ステロイド
US7521439B2 (en) Glucocorticoid receptor ligands for the treatment of metabolic disorders
US7534779B2 (en) Quinol compound and pharmaceutical composition
AU751708B2 (en) Pregnane glucuronides
KR100530816B1 (ko) 4-할로겐화 17-메틸렌 스테로이드, 그의 제조 방법 및그를 포함하는 제약 조성물
WO2013133980A1 (en) Nitroxy derivatives of soft steroids
WO2007098384A2 (en) Tetracyclic steroid derivatives useful as progesterone receptor modulators

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20141224

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20141224